Hydroxyapatite-ceramic-coated femoral components in young patients followed-up for 16 to 19 years: an update of a previous report.
In 2004 we described the ten-year prospective results of 38 total hip replacements using the Furlong hydroxyapatite-ceramic-coated femoral component in 35 patients < 50 years old. We have now reviewed the surviving 35 arthroplasties in 33 patients at a mean of 16 years (10.3 to 19.9). The mean age of the surviving patients at the time of operation was 41.3 years (26.0 to 49.0). Of these, eight have undergone revision of their acetabular component for aseptic loosening. None of the femoral components has had revision for aseptic loosening giving a survival rate of 100% at 16 years (95% confidence interval 89% to 100%). The Furlong hydroxyapatite-ceramic-coated femoral component gives excellent long-term survival in young and active patients.
Shah
N N
NN
Worthing & Southlands Hospitals NHS Trust, Southlands Hospital, Upper Shoreham Road, Shoreham-by-Sea, West Sussex BN43 6TQ, UK. nns5511@aol.com
Edge
A J
AJ
Clark
D W
DW
D000328:Adult; D019644:Arthroplasty, Replacement, Hip / Q000379:methods; D002516:Ceramics / Q000627:therapeutic use*; D020099:Coated Materials, Biocompatible / Q000627:therapeutic use*; D017886:Durapatite / Q000627:therapeutic use*; D005260:Female; D005500:Follow-Up Studies; D006621:Hip Joint / Q000000981:diagnostic imaging / Q000601:surgery*; D006622:Hip Prosthesis; D006801:Humans; D008297:Male; D008875:Middle Aged; D011859:Radiography; D016019:Survival Analysis; D016896:Treatment Outcome; D055815:Young Adult
D020099:Coated Materials, Biocompatible; D017886:Durapatite